文献速递胸部肿瘤

非小细胞肺癌患者接受PD-1/PD-L1抑制剂后挽救化疗的缓解率提高

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-10-31

该研究纳入73例非小细胞肺癌患者,比较免疫治疗后挽救化疗(SCAI)与免疫治疗前末次化疗(LCBI)的客观缓解率。结果显示SCAI的ORR为53.4%,显著高于LCBI的34.9%(p=0.03),提示PD-1/PD-L1抑制剂可能使肿瘤对后续化疗更敏感。

要点

  • 免疫治疗后挽救化疗的ORR显著高于免疫治疗前末次化疗。
  • 铂类双药亚组中SCAI与LCBI的ORR差异显著(66.7% vs 39.5%,p=0.03)。
  • 非铂单药亚组中SCAI的ORR数值更高但差异未达统计学显著(p=0.09)。

核心结论

  • 免疫治疗后挽救化疗的客观缓解率显著高于免疫治疗前末次化疗,提示PD-1/PD-L1抑制剂可能增强后续化疗敏感性。

研究设计与样本

  • 回顾性分析纳入73例具有挽救化疗缓解数据的非小细胞肺癌患者。
  • 其中10例以PD-1/PD-L1抑制剂为一线治疗,63例有免疫治疗前末次化疗的缓解数据。

主要发现

  • 73例接受挽救化疗的患者中39例(53.4%)达到客观缓解,而免疫治疗前末次化疗的ORR为34.9%(22/63),p=0.03。
  • 铂类双药亚组中,挽救化疗与末次化疗的ORR分别为66.7%(16/24)和39.5%(17/43),p=0.03。
  • 非铂单药亚组中,挽救化疗与末次化疗的ORR分别为46.9%(23/49)和25.0%(5/20),p=0.09。

临床怎么用

  • 对于既往接受过PD-1/PD-L1抑制剂治疗的非小细胞肺癌患者,后续化疗仍可能获得较高缓解率。
  • 临床决策时可考虑免疫治疗后序贯化疗的策略,但需结合患者具体情况。

局限性

  • 研究为回顾性设计,样本量较小(73例),可能存在选择偏倚。
  • 非铂单药亚组的差异未达统计学显著,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have shown some efficacy in treating advanced NSCLC, their benefits are limited to only a subset of patients. Advanced NSCLC is generally treated with a chemotherapy and immunotherapy series. Here we evaluated whether PD-1/PD-L1 inhibitors affect the antitumor effects of salvage chemotherapy administered after immunotherapy (SCAI) in patients with NSCLC. METHODS: This study included patients with available SCAI response data. We compared the SCAI objective response rates (ORRs) with the ORRs after the last chemotherapy administered before immunotherapy (LCBI). RESULTS: In total, 73 patients met the inclusion criteria and were included in the analyses. Of these patients, 10 received PD-1/PD-L1 inhibitors as first-line therapy and the remaining 63 had available LCBI response data. Of the 73 patients treated with SCAI, 39 (53.4%) achieved the ORR, whereas the ORR of LCBI was 34.9% (22 of 63) (p = 0.03). We also compared the ORRs of the SCAI and LCBI groups after stratification into platinum doublet therapy versus nonplatinum monotherapy. The ORRs for platinum doublet SCAI and LCBI therapies were 66.7% (16 of 24) and 39.5% (17 of 43), respectively (p = 0.03), whereas for nonplatinum SCAI and LCBI monotherapies they were 46.9% (23 of 49) and 25.0% (5 of 20), respectively (p = 0.09). CONCLUSIONS: The ORR for SCAI was significantly higher than that for LCBI. These data indicate that anti-PD-1/PD-L1 inhibitors could make tumors more vulnerable to subsequent chemotherapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Park SE, Lee SH, Ahn JS, et al. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 29101058. doi:10.1016/j.jtho.2017.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。